Magenta Therapeutics Inc (NASDAQ:MGTA) Insider Michael P. Cooke Sells 7,500 Shares

Magenta Therapeutics Inc (NASDAQ:MGTA) insider Michael P. Cooke sold 7,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $13.00, for a total value of $97,500.00. Following the completion of the transaction, the insider now directly owns 244,396 shares of the company’s stock, valued at approximately $3,177,148. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Magenta Therapeutics stock opened at $12.44 on Tuesday. The stock has a 50 day moving average of $10.87 and a 200 day moving average of $12.29. Magenta Therapeutics Inc has a 12 month low of $5.31 and a 12 month high of $21.00. The firm has a market cap of $516.22 million, a PE ratio of -3.97 and a beta of 3.24.

Magenta Therapeutics (NASDAQ:MGTA) last announced its quarterly earnings results on Wednesday, November 13th. The company reported ($0.54) EPS for the quarter, meeting analysts’ consensus estimates of ($0.54). On average, sell-side analysts predict that Magenta Therapeutics Inc will post -2.01 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in MGTA. Metropolitan Life Insurance Co NY bought a new position in Magenta Therapeutics during the third quarter valued at approximately $76,000. JPMorgan Chase & Co. boosted its stake in Magenta Therapeutics by 52.8% during the second quarter. JPMorgan Chase & Co. now owns 5,349 shares of the company’s stock valued at $79,000 after buying an additional 1,848 shares during the last quarter. OneAscent Financial Services LLC bought a new position in Magenta Therapeutics during the second quarter valued at approximately $166,000. Virtus ETF Advisers LLC bought a new position in Magenta Therapeutics during the second quarter valued at approximately $274,000. Finally, Wells Fargo & Company MN boosted its stake in Magenta Therapeutics by 253.1% during the second quarter. Wells Fargo & Company MN now owns 30,021 shares of the company’s stock valued at $443,000 after buying an additional 21,519 shares during the last quarter. 64.81% of the stock is owned by institutional investors.

A number of research firms have recently weighed in on MGTA. Zacks Investment Research lowered Magenta Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 15th. ValuEngine lowered Magenta Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. Finally, Cowen reaffirmed a “buy” rating on shares of Magenta Therapeutics in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $16.33.

Magenta Therapeutics Company Profile

Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.

See Also: Systematic Risk and Investors

Insider Buying and Selling by Quarter for Magenta Therapeutics (NASDAQ:MGTA)

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.